CRISPR Therapeutics AG and Vertex Pharmaceuticals Inc to Host AG Phase 1/2 CTX001™ Investor Update Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the CTX001 Investor Event, sponsored by Vertex and CRISPR Therapeutics. (Operator Instructions) Please be advised that today's conference maybe recorded.
I would now like to hand the conference over to your speaker today, Mr. Michael Partridge, Senior Vice President of Investor Relations. Please go ahead, sir.
Good morning. This is Michael Partridge of Vertex. Susan Kim, Vice President of Investor Relations for CRISPR Therapeutics, and I are pleased to introduce today's call which will focus on the groundbreaking clinical data for our investigational gene-editing treatment, CTX001, in the treatment of sickle cell disease and beta thalassemia.
Providing prepared remarks on the call today are Dr. Reshma Kewalramani, Vertex's CEO and President; Dr. Haydar Frangoul, Medical Director of Pediatric Hematology and Oncology at Sarah Cannon Research Institute; and Dr. Sam Kulkarni, Chief Executive Officer of CRISPR
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |